Subtitle site (optional)
Artificial pancreas for
type-1 diabeticsDiabeloop’s connected artificial pancreas will
improve blood-sugar regulation and enhance
quality of life for type-1 diabetics.
The artificial pancreas developed by Diabeloop
is made up of a continuous glucose sensor and
a miniature patch insulin pump connected by
Bluetooth to a dedicated smartphone equipped with
algorithms developed by Diabeloop in partnership
with Leti to calculate insulin doses and send the
information to the pump automatically. The data
are also sent to a patient monitoring center.
The technology brings a major change for type1
diabetics who, until now, had to test their blood
sugar themselves many times throughout the day.
Diabeloop’s artificial pancreas will give patients the
peace of mind of knowing all they have to do is tell
the system about their meals and physical activity
and their blood sugar will be regulated much more
effectively than before.
The efficacy of Diabeloop’s artificial pancreas has
been confirmed by several clinical trials (2014,
2016, and 2017). The company is now working to
obtain the CE mark, a necessary prerequisite to
the product’s commercial release. Diabeloop has
partnerships with diabetes treatment research
center CERITD and around a dozen university
medical centers, and has a joint lab with LetiWebsiteContact: Marc Julien
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.